Alectinib for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status

被引：0

作者：

Kenmotsu, H. ^{[1
]}

Iwama, E. ^{[2
]}

Goto, Y. ^{[3
]}

Harada, T. ^{[4
]}

Tsumura, S. ^{[5
]}

Sakashita, H. ^{[6
]}

Mori, Y. ^{[7
]}

Nakagaki, N. ^{[8
]}

Fujita, Y. ^{[9
]}

Seike, M. ^{[10
]}

Bessho, A. ^{[11
]}

Ono, M. ^{[12
]}

Okazaki, A. ^{[13
]}

Akamatsu, H. ^{[14
]}

Morinaga, R. ^{[15
]}

Ushijima, S. ^{[16
]}

Shimose, T. ^{[17
]}

Tokunaga, S. ^{[18
]}

Hamada, A. ^{[19
]}

Yamamoto, N. ^{[20
]}

Nakanishi, Y. ^{[2
]}

Sugio, K. ^{[21
]}

Okamoto, I. ^{[2
]}

机构：

[1] Shizuoka Canc Ctr, Shizuoka, Japan

[2] Kyushu Univ, Fukuoka, Fukuoka, Japan

[3] Natl Canc Ctr, Tokyo, Japan

[4] Jcho Kyushu Hosp, Kitakyushu, Fukuoka, Japan

[5] Kumamoto Reg Med Ctr, Kumamoto, Japan

[6] Tokyo Med & Dent Univ, Tokyo, Japan

[7] Iwate Prefectural Cent Hosp, Morioka, Iwate, Japan

[8] Steel Mem Yawata Hosp, Kitakyushu, Fukuoka, Japan

[9] Asahikawa Med Ctr, Asahikawa, Hokkaido, Japan

[10] Nippon Med Sch, Tokyo, Japan

[11] Japanese Red Cross Okayama Hosp, Resp Med, Okayama, Japan

[12] Kesennuma City Hosp, Kesennuma, Miyagi, Japan

[13] Ishikawa Prefectural Cent Hosp, Kanazawa, Ishikawa, Japan

[14] Wakayama Med Univ, Dept Internal Med 3, Wakayama, Japan

[15] Oita Prefectural Hosp, Oita, Japan

[16] Fukuoka Univ, Chikushi Hosp, Chikushino, Japan

[17] Clin Res Support Ctr, Fukuoka, Fukuoka, Japan

[18] Kyushu Univ Hosp, Fukuoka, Fukuoka, Japan

[19] Natl Canc Ctr, Tokyo, Japan

[20] Wakayama Med Coll, Dept Internal Med 3, Wakayama, Japan

[21] Oita Univ, Oita, Japan

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期

关键词：

Alectinib; poor performance status; ALK rearrangement;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1.03-004

引用

页码：S1951 / S1951

页数：1

共 50 条

[1] Alectinib for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status (Lung Oncology Group in Kyushu 1401)
Iwama, Eiji
Goto, Yasushi
Murakami, Haruyasu
Harada, Taishi
Tsumura, Shinsuke
Sakashita, Hiroyuki
Mori, Yoshiaki
Nakagaki, Noriaki
Fujita, Yuka
Seike, Masahiro
Bessho, Akihiro
Ono, Manabu
Okazaki, Akihito
Akamatsu, Hiroaki
Morinaga, Ryotaro
Ushijima, Shinichiro
Shimose, Takayuki
Tokunaga, Shoji
Hamada, Akinobu
Yamamoto, Nobuyuki
Nakanishi, Yoichi
Sugio, Kenji
Okamoto, Isamu
[J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (07) : 1161 - 1166
[2] Survival Analysis for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status Treated with Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401
Iwama, Eiji
Goto, Yasushi
Murakami, Haruyasu
Tsumura, Shinsuke
Sakashita, Hiroyuki
Mori, Yoshiaki
Nakagaki, Noriaki
Fujita, Yuka
Seike, Masahiro
Bessho, Akihiro
Ono, Manabu
Nishitsuji, Masaru
Akamatsu, Hiroaki
Morinaga, Ryotaro
Akagi, Takanori
Shimose, Takayuki
Tokunaga, Shoji
Yamamoto, Nobuyuki
Nakanishi, Yoichi
Sugio, Kenji
Okamoto, Isamu
[J]. ONCOLOGIST, 2020, 25 (04): : 306 - +
[3] Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib
Watanabe, Satomi
Hayashi, Hidetoshi
Okamoto, Kunio
Fujiwara, Kimiko
Hasegawa, Yoshikazu
Kaneda, Hiroyasu
Tanaka, Kaoru
Takeda, Masayuki
Nakagawa, Kazuhiko
[J]. CLINICAL LUNG CANCER, 2016, 17 (06) : 528 - 534
[4] Crizotinib for ALK rearrangement-positive non-small cell lung cancer patients with central nervous system metastasis
Takeda, Masayuki
Nakagawa, Kazuhiko
[J]. TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S554 - S556
[5] Transformation of ALK rearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinib
Takegawa, N.
Hayashi, H.
Iizuka, N.
Takahama, T.
Ueda, H.
Tanaka, K.
Takeda, M.
Nakagawa, K.
[J]. ANNALS OF ONCOLOGY, 2016, 27 (05) : 953 - 955
[6] Clinical effect of alectinib in patients with ALK-positive non-small cell lung cancer
Nishi, Koichi
[J]. ANNALS OF ONCOLOGY, 2019, 30
[7] AlectinibTransformation of ALK rearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinib : case report
[J]. Reactions Weekly, 2016, 1607 (1) : 35 - 35
[8] Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement-positive non-small cell lung cancer treated with alectinib
Yamamoto, Yuzo
Okamoto, Isamu
Otsubo, Kohei
Iwama, Eiji
Hamada, Naoki
Harada, Taishi
Takayama, Koichi
Nakanishi, Yoichi
[J]. INVESTIGATIONAL NEW DRUGS, 2015, 33 (05) : 1148 - 1150
[9] Brigatinib and Alectinib for ALK Rearrangement-Positive Advanced Non-Small Cell Lung Cancer with or without Central Nervous System Metastasis: A Systematic Review and Network Meta-Analysis
Ando, Koichi
Akimoto, Kaho
Sato, Hiroki
Manabe, Ryo
Kishino, Yasunari
Homma, Tetsuya
Kusumoto, Sojiro
Yamaoka, Toshimitsu
Tanaka, Akihiko
Ohmori, Tohru
Sagara, Hironori
[J]. CANCERS, 2020, 12 (04)
[10] Serum ProGRP and NSE levels predicting small cell lung cancer transformation in a patient with ALK rearrangement-positive non-small cell lung cancer: A case report
Oya, Yuko
Yoshida, Tatsuya
Uemura, Takehiro
Murakami, Yoshiko
Inaba, Yoshitaka
Hida, Toyoaki
[J]. ONCOLOGY LETTERS, 2018, 16 (04) : 4219 - 4222

← 1 2 3 4 5 →